Suchergebnisse - "F0P408N6V4"

PubPharm (13)

1

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

enthalten in: Blood advances | 2023

von Yamshon, S. | Chen, G. | Gribbin, C. | +9

2

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bhutani, M. | Foureau, D. | Robinson, M. | +14

3

Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy : Does Lenalidomide Protect From Severe COVID-19?

enthalten in: Hematology/oncology and stem cell therapy | 2023

von Tailor, I. | Alshehry, N. | Zaidi, S. | +4

4

Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2

enthalten in: Expert review of vaccines | 2022

von Kos, I. | Kiefer, M. | Brill, K. | +10

5

Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor : A Report From The Covid Era

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Rybinski, B. | Rapoport, A. | Badros, A. | +2

6

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) : a randomised, head-to-head, open-label, phase 3 study

enthalten in: The Lancet. Haematology | 2022

von Schjesvold, F. | Dimopoulos, M. | Delimpasi, S. | +126

CommentIn: Lancet Haematol. 2022 Feb;9(2):e82-e84. - PMID 35032433

7

Recent advances in drug repurposing using machine learning

enthalten in: Current opinion in chemical biology | 2021

von Urbina, F. | Puhl, A. | Ekins, S.

8

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs : single-center experience

enthalten in: Annals of hematology | 2021

von Krejci, M. | Pour, L. | Adam, Z. | +6

9

Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime

enthalten in: Orvosi hetilap | 2021

von Hardi, A. | Varga, G. | Nagy, Z. | +9

10

Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses

enthalten in: Signal transduction and targeted therapy | 2021

von Su, S. | Chen, J. | Wang, Y. | +4

CommentOn: Cell Res. 2021 Feb;31(2):126-140. - PMID 33420426